Estrogen receptor-alpha-interacting cytokeratins potentiate the antiestrogenic activity of fulvestrant.
Fulvestrant (ICI 182, 780) is a selective estrogen receptor downregulator (SERD) and potent antiestrogen. In estrogen receptor-alpha-positive ERalpha(+) breast cancer, the drug immobilizes ERalpha in the nuclear matrix, inducing receptor polyubiquitination and subsequent degradation via the 26S proteasome. We previously reported that fulvestrant-induced ERalpha degradation depends on the interaction of ERalpha with cytokeratins 8 and 18 (CK8/CK18). Here we further investigate the role of these two cytokeratins in the antagonistic activity of the SERD. Using ER-responsive reporter assays, we demonstrate greater antiestrogenic activity of fulvestrant in CK8/CK18(+) vs. CK8/CK18(-) cancer cells and loss of CK8/CK18 expression was observed in a breast cancer cell model for acquired fulvestrant resistance. In contrast, the presence of CK8/CK18 had no effect on the antiestrogenic activity of 4-hydroxytamoxifen, which was unable to induce an interaction between these CKs and ERalpha. By utilizing the ligand activity inversion ERalpha mutant L540Q to further examine the mechanism of fulvestrant action, we demonstrate that the ERalpha mutant does not interact with CK8/CK18 in the presence of fulvestrant and L540Q is not immobilized to the nuclear matrix after antiestrogen treatment. In transcription assays, fulvestrant displayed agonist activity, stimulating L540Q-mediated gene expression. In addition, fulvestrant did not induce an ERbeta interaction with CK8/CK18 and subsequent ERbeta degradation. Collectively, these results suggest that CK8/18 play an important role in the antiestrogenic action of fulvestrant in breast cancer cells and that these two cytokeratins could serve as prognostic markers for SERD therapy response in breast cancer patients.
Long
Xinghua
X
Medical Sciences, Indiana University School of Medicine, Bloomington, IN, USA.
Fan
Meiyun
M
Nephew
Kenneth P
KP
D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism; D004958:Estradiol / Q000031:analogs & derivatives; D004965:Estrogen Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D020847:Estrogen Receptor Modulators / Q000494:pharmacology / Q000627:therapeutic use; D047628:Estrogen Receptor alpha / Q000235:genetics / Q000378:metabolism*; D047629:Estrogen Receptor beta / Q000235:genetics / Q000378:metabolism; D005260:Female; D000077267:Fulvestrant; D006801:Humans; D007633:Keratins / Q000235:genetics / Q000378:metabolism / Q000494:pharmacology; D009841:Oligonucleotides; D046988:Proteasome Endopeptidase Complex; D011960:Receptors, Estrogen / Q000235:genetics / Q000378:metabolism*; D013629:Tamoxifen / Q000031:analogs & derivatives
C506487:ESR1 protein, human; D004965:Estrogen Antagonists; D020847:Estrogen Receptor Modulators; D047628:Estrogen Receptor alpha; D047629:Estrogen Receptor beta; D009841:Oligonucleotides; D011960:Receptors, Estrogen; C116746:phosphodiester alpha; D013629:Tamoxifen; C016601:afimoxifene; D000077267:Fulvestrant; D004958:Estradiol; D007633:Keratins; D046988:Proteasome Endopeptidase Complex; C061553:ATP dependent 26S protease